BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 20, 2021
View Archived Issues
ConserV and Lawrence Livermore National Laboratory collaborate on broad-spectrum coronavirus vaccine
Read More
Dosing begins in phase I/II study of TP-0184 as treatment of anemia in patients with MDS
Read More
GC-019-F autologous CAR T-cell therapy receives IND approval in China
Read More
First patient dosed in second phase II study of AD-109 in obstructive sleep apnea
Read More
FDA clears IND application for TERN-501 to be developed as treatment for NASH
Read More
European Commission approves Enhertu for HER2-positive breast cancer
Read More
Ivermectin found useful in patients with nonsevere COVID-19 disease
Read More
Bayer synthesizes new P2X3 receptor antagonists
Read More
New IL-17 modulators discovered at UCB
Read More
ZM-32, a novel muscone derivative that inhibits breast tumor angiogenesis in vivo
Read More
Shanghai Pharmaceuticals Holding patents Wee1-like protein kinase inhibitors
Read More
IMPACT Therapeutics identifies ATR kinase inhibitors
Read More
Organ-on-a-chip bests standard toxicity tests
Read More
Shanghai Jemincare Pharmaceuticals, Jiangxi Jemincare Group present factor XIa inhibitors
Read More
FDA accepts IND application for PBCAR19B for NHL
Read More
Targeting the cartilage EGFR pathway is a promising therapeutic strategy in OA
Read More
GPR68-PKC pathway protects the brain from acidosis-induced neuronal injury
Read More
Gemcitabine can be repurposed as anti-HEV agent, in particular for HEV-infected cancer patients
Read More
New SIRP-alpha antibodies inducing tumor cell phagocytosis without affecting T-cell functionality
Read More
Caladrius opens phase IIb trial of CLBS-16 for coronary microvascular dysfunction
Read More
Lixte and City of Hope enter agreement to study LB-100 in phase Ib study for extensive stage SCLC
Read More
Clinical hold for planned phase I/II trial of HST-003 for knee cartilage regeneration
Read More
LMR-101 ameliorates symptoms of epilepsy in rodents
Read More
Aclaris reports topline phase IIa data on ATI-450 for rheumatoid arthritis
Read More
FDA approves Verquvo for heart failure
Read More
Aptorum cleared to begin phase I study in Canada with ALS-4 for S. aureus infections
Read More